Live corpus
Active intelligence prompt Pediatric cancer: surface high-value therapeutic signals across pediatric oncology literature.
PEDIATRIC CANCER RESEARCH INTELLIGENCE

Finding therapies hidden in 40,029 pediatric cancer papers.

Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.

40,029 Papers indexed
1,440 Papers AI scored
40,029 Ranked papers
100.0% Coverage
PATIENT-FRIENDLY SUMMARY

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

For education only—not personal medical advice.

LIVE PEDIATRIC ONCOLOGY INTELLIGENCE
↑ Therapeutic signals emerging ↑ New pediatric cancer papers ingested ↑ Cross-paper convergence detected ↑ Human relevance scores updating ↑ Overlooked treatment paths surfacing
TOP PEDIATRIC CANCER SIGNALS

Ranked Discovery Journal Articles

View all discoveries →
PEDIATRIC CANCER RESEARCH TERMINAL

All ranked pediatric cancer papers

40029 results
B
Of travelling homeoproteins and medulloblastomas.
PMID 40760093 Published: 2025-08-04 Ingested: 2026-08-02 12:05 AM Oncogene
AI -
Standard 74.6
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 74.6/100. Study design: 95.0; human relevance: 75.0; therapeutic relevance: 33.0; sample size: 60.0; recency: 100.0; abstract quality: 85.0.

B
Prolactin serum concentrations in childhood-onset craniopharyngioma patients.
PMID 40481916 Published: 2025-06-07 Ingested: 2026-08-02 12:04 AM Journal of endocrinological investigation
AI -
Standard 74.6
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 74.6/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 33.0; sample size: 20.0; recency: 90.0; abstract quality: 100.0.

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 74.6/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 80.5; sample size: 60.0; recency: 90.0; abstract quality: 100.0.

B
Validated Integration of Tumor Deposits in N Staging for Prognostication in Colon Cancer.
PMID 39908058 Published: 2025-04-01 Ingested: 2026-08-02 12:12 AM JAMA surgery
AI -
Standard 74.6
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 74.6/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 38.0; sample size: 90.0; recency: 90.0; abstract quality: 100.0.

B
Feasibility, safety, and efficacy of dietary or lifestyle interventions for hypothalamic obesity: A systematic review.
PMID 38955055 Published: 2024-05-27 Ingested: 2026-08-02 12:02 AM Clinical nutrition (Edinburgh, Scotland)
AI -
Standard 74.6
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 74.6/100. Study design: 95.0; human relevance: 75.0; therapeutic relevance: 35.5; sample size: 60.0; recency: 80.0; abstract quality: 100.0.

B
AI -
Standard 74.58
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 74.6/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 80.4; sample size: 20.0; recency: 90.0; abstract quality: 85.0.

B
Reducing drug-related problems in hospitalized pediatric cancer patients through clinical pharmacist interventions: An interventional study from Turkey.
PMID 41026961 Published: 2025-09-30 Ingested: 2026-08-02 12:05 AM Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
AI -
Standard 74.56
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 74.6/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 80.3; sample size: 50.0; recency: 100.0; abstract quality: 100.0.

B
Association of Medicaid Expansion With Timely Receipt of Treatment and Survival Among Patients With HR-Negative, HER2-Positive Breast Cancer.
PMID 39447607 Published: 2024-10-23 Ingested: 2026-08-02 12:02 AM Journal of the National Comprehensive Cancer Network : JNCCN
AI -
Standard 74.56
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 74.6/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 60.3; sample size: 100.0; recency: 90.0; abstract quality: 100.0.

B
Circulating Interleukin-37 as a Biomarker Candidate for Hepatocellular Carcinoma in Decompensated Advanced Chronic Liver Disease.
PMID 42073372 Published: 2026-03-30 Ingested: 2026-08-02 12:06 AM Life (Basel, Switzerland)
AI -
Standard 74.55
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 74.6/100. Study design: 80.0; human relevance: 95.0; therapeutic relevance: 22.8; sample size: 70.0; recency: 100.0; abstract quality: 100.0.

B
AI -
Standard 74.54
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 74.5/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 50.2; sample size: 20.0; recency: 90.0; abstract quality: 65.0.

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 74.5/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 90.2; sample size: 40.0; recency: 90.0; abstract quality: 100.0.

Previous
Page 411 of 3336
Next
Before you continue

AI-assisted research information

Neurocompute uses AI to summarize scientific papers, interpret research signals, and suggest relevant reference links. AI-generated content can be incomplete, misleading, or wrong, and generated links may be irrelevant or unavailable.

Our reviewed outputs have performed strongly to date, but past accuracy is not a guarantee. Verify summaries, scores, claims, and links against the original publication before relying on them.

This platform is for research and education only. It does not provide medical advice, diagnosis, treatment recommendations, or clinical guidance.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic